Search the Newsreel

BioRestorative Therapies (BRTX) delays Q2 10-Q amid losses and going-concern risk

Taysha Gene Therapies (TSHA) Stock Retreats As Cash Burn Deepens

Morgan Stanley (TSHA holder) discloses 5.1% Taysha Gene Therapies stake in 13G/A

Morgan Stanley and its subsidiary Morgan Stanley Capital Services LLC have reported a beneficial ownership of 16,244,339 shares, or 5.1%, of Taysha Gene Therapies, Inc. common stock as of June 30, 2026. This disclosure was made in an Amendment No. 2 to Schedule 13G …

Taysha Gene Therapies (TSHA) Stock Trades At A Premium Despite A 232% Return

Taysha Gene Therapies (TSHA) has seen a significant 232% return over three years, yet its current valuation, particularly its Price-to-Book ratio of 9.8x against an industry average of 2.5x, suggests it trades at a premium. The company's valuation appears to already price in expectations …

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down Following Weak Earnings

Taysha Gene Therapies, Inc. Stock 12‑Month Price Target Raised to $13.33, Implies 100% Upside

Taysha Gene Therapies, Inc.'s stock has seen its average 12-month price target increased to $13.33, up from $13.25, according to 12 analysts. This new target implies a potential 100% upside based on the Aug. 11 closing price. The consensus rating for the stock remains …

Renaissance Technologies LLC Purchases 242,103 Shares of Taysha Gene Therapies, Inc. $TSHA

Renaissance Technologies LLC significantly increased its stake in Taysha Gene Therapies (NASDAQ: TSHA) by 141.5% in the first quarter, acquiring an additional 242,103 shares. This brings their total holding to 413,203 shares valued at approximately $1.85 million. Despite this institutional confidence and a consensus …

Taysha Gene Therapies Inc (TSHA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Taysha outlines REVEAL 6-month interim analysis and FDA feedback in H1 2027 while targeting PPQ completion in Q4 2026

Earnings Call Insights: Taysha Gene Therapies (TSHA) Q2 2026 MANAGEMENT VIEW * "The second quarter of 2026 was a highly productive period for Taysha," said CEO Sean Nolan, highlighting "the completion of dosing in both the REVEAL pivotal and ASPIRE trials" and progress "toward …

Earnings call transcript: Taysha Gene Therapies misses Q2 2026 EPS forecast

Taysha Gene Therapies (TSHA) reported a wider second-quarter loss for 2026, missing Wall Street's EPS forecast by $0.01, with shares falling 6.44% in after-hours trading. Despite the earnings miss, the company highlighted significant clinical progress with its lead Rett syndrome gene therapy, TSHA-102, completing …

Taysha Gene Therapies Q2 Results: Net Loss Widens To $46.6 Million

Taysha Gene Therapies reported a widening net loss of $46.6 million in Q2 2026, missing EPS estimates, primarily due to increased R&D spending on its lead candidate TSHA-102 for Rett syndrome. Despite the losses, the company strengthened its cash reserves to $455.4 million through …

Earnings Flash (TSHA) Taysha Gene Therapies Posts Q2 Loss of $0.13, vs. FactSet Est of $0.11 Loss

Taysha Gene Therapies (TSHA) reported a Q2 loss of $0.13 per share, which is wider than the FactSet estimate of a $0.11 loss. This financial update indicates that the company's performance for the second quarter of 2026 fell short of analyst expectations. The article …

Taysha Gene Therapies (NASDAQ:TSHA) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Taysha Gene Therapies (NASDAQ:TSHA) reported a quarterly loss of $0.13 per share, missing analyst expectations by $0.02. Despite this, the stock rose 5.3% to $6.71, supported by strong liquidity and significant institutional ownership. Analyst sentiment is generally positive, with an average "Buy" rating and …

Taysha Gene Therapies Q2 net loss widens on higher R&D costs

Taysha Gene Therapies reported a widening net loss in the second quarter due to increased research and development costs. The article, sourced from Reuters and provided via TradingView, indicates that the full details are available to subscribers.

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Taysha Gene Therapies announced its second-quarter 2026 financial results, highlighting the completion of dosing in its pivotal REVEAL and ASPIRE trials for TSHA-102 in Rett syndrome. The company expects to report topline data and FDA feedback on the BLA submission pathway in the first …

Taysha Gene Therapies (TSHA) Is Up 10.2% After Securing Long-Term TSHA-102 Manufacturing Capacity

Taysha Gene Therapies (TSHA) saw a 10.2% stock increase after announcing a commercial supply agreement with Catalent for the manufacturing of TSHA-102, its investigational Rett syndrome gene therapy. This deal secures long-term GMP capacity, preparing Taysha for potential commercialization, though the company remains loss-making …

Taysha Gene faces earnings test as Rett therapy advances

Taysha Gene Therapies Inc. (TSHA) is set to report its second-quarter earnings, with investor focus primarily on the progress of its lead gene therapy candidate, TSHA-102, for Rett syndrome, rather than its financial results. Analysts expect a loss of $0.12 per share on $300,000 …

BioRestorative Therapies Inc expected to post a loss of 12 cents a share - Earnings Preview

BioRestorative Therapies Inc (BRTX) is anticipated to report an earnings loss of 12 cents per share. This information comes from a Refinitiv earnings preview. The full article, originally from Reuters, is available on TradingView.

BioRestorative Therapies Inc (BRTX) Stock News Today

This article provides current stock information for BioRestorative Therapies Inc (BRTX), including its latest stock price, market capitalization, and a note that more news is coming soon. It serves as a placeholder for financial news and analyst ratings related to the company. The page …

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on August …

Taysha Gene Therapies, Inc. (TSHA): Investor Outlook Reveals A Potential 108.99% Upside

Taysha Gene Therapies, Inc. (TSHA), a clinical-stage biotechnology firm, is attracting investor attention due to its promising pipeline in adeno-associated virus-based gene therapies for severe monogenic central nervous system diseases. Despite current negative financial metrics typical of developmental biotech firms, analysts project a potential …

BioRestorative Therapies Inc (BRTX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Manufacturing deal prepares Rett gene therapy for potential U.S. launch

Taysha Gene Therapies has announced a commercial supply agreement with Catalent to prepare for the potential U.S. launch of TSHA-102, an experimental gene therapy for Rett syndrome. Catalent will serve as the primary commercial manufacturer if TSHA-102 receives FDA approval, building on their existing …

Taysha Sets Aug. 11 Webcast on Rare-Disease Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) will report its second-quarter 2026 financial results and host a corporate update conference call and webcast on Tuesday, August 11, 2026, at 4:30 PM Eastern Time. The company, focused on AAV-based gene therapies for severe monogenic CNS diseases, will …

Taysha Gene Therapies (TSHA) to Announce Quarterly Earnings on Tuesday

Taysha Gene Therapies to Release Second Quarter 2026

Taysha Gene Therapies announced it will report its second-quarter 2026 financial results and host a conference call and webcast on Tuesday, August 11, 2026, at 4:30 PM Eastern Time. The clinical-stage biotechnology company focuses on developing AAV-based gene therapies for severe monogenic diseases of …

Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome

Taysha Gene Therapies and Catalent have expanded their strategic partnership to include commercial manufacturing support for TSHA-102, Taysha’s gene therapy for Rett syndrome. Catalent will serve as the primary commercial manufacturer following potential FDA approval, ensuring long-term capacity and a scalable supply. This agreement …

BioRestorative Therapies (BRTX) investor Alta Partners reports 4.99% ownership cap

Alta Partners LLC has filed an amended Schedule 13G, reporting beneficial ownership of 1,338,133 shares of BioRestorative Therapies, Inc. common stock, which represents 4.99% of the class. This percentage is capped due to a beneficial ownership limitation in an applicable warrant. Steven Cohen, Managing …

Taysha secures commercial manufacturing deal with Catalent

Taysha Gene Therapies announced a commercial supply agreement with Catalent, Inc. for TSHA-102, an investigational gene therapy for Rett syndrome. Catalent will serve as Taysha’s primary commercial manufacturer after potential U.S. FDA approval, providing GMP manufacturing and commercial supply from its facility in Harmans, …

Taysha’s Rett Gene Therapy Gets a Future Commercial Manufacturer

Taysha Gene Therapies and Catalent have expanded their partnership with a commercial supply agreement for TSHA-102, an investigational gene therapy for Rett syndrome. Under the agreement, Catalent will serve as the primary commercial manufacturer for TSHA-102 following potential U.S. FDA approval, leveraging its FDA-licensed …

Catalent, Taysha extend AAV-based gene therapy partnership

Taysha Gene Therapies and Catalent have announced a commercial supply agreement for TSHA-102, Taysha’s investigational gene therapy for Rett syndrome. This agreement extends their partnership, securing long-term manufacturing capacity and a scalable supply framework for TSHA-102 after potential FDA approval. Catalent will provide GMP …

Happiest Minds posts 14.3% revenue growth in Q1FY27

Taysha Gene Therapies Inc (TSHA) Institutional Confidence

Taysha Gene Therapies Inc (TSHA) has an institutional shareholding score of 10.00, ranking 1st in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 100.06%, showing a 1.93% increase quarter-over-quarter. Steven Cohen is the largest institutional shareholder, holding 358.26K shares.